DE69613347T2 - Bizyklisch substituierte hexahydrobenz(e)isoindole mit alpha-1-adrenerg antagonistischer wirkung - Google Patents
Bizyklisch substituierte hexahydrobenz(e)isoindole mit alpha-1-adrenerg antagonistischer wirkungInfo
- Publication number
- DE69613347T2 DE69613347T2 DE69613347T DE69613347T DE69613347T2 DE 69613347 T2 DE69613347 T2 DE 69613347T2 DE 69613347 T DE69613347 T DE 69613347T DE 69613347 T DE69613347 T DE 69613347T DE 69613347 T2 DE69613347 T2 DE 69613347T2
- Authority
- DE
- Germany
- Prior art keywords
- alpha
- bizyclically
- isoindole
- antagonistic effect
- adrenergic antagonistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/379,823 US5521181A (en) | 1995-01-27 | 1995-01-27 | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
US08/465,476 US5792767A (en) | 1995-01-27 | 1995-06-05 | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
PCT/US1996/000178 WO1996022991A1 (en) | 1995-01-27 | 1996-01-11 | Bicyclic substituted hexahydrobenz[e]isoindole alpha-1- adrenergic antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69613347D1 DE69613347D1 (de) | 2001-07-19 |
DE69613347T2 true DE69613347T2 (de) | 2002-04-18 |
Family
ID=27008783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69613347T Expired - Fee Related DE69613347T2 (de) | 1995-01-27 | 1996-01-11 | Bizyklisch substituierte hexahydrobenz(e)isoindole mit alpha-1-adrenerg antagonistischer wirkung |
Country Status (15)
Country | Link |
---|---|
US (1) | US5792767A (de) |
EP (1) | EP0805812B1 (de) |
JP (1) | JPH11501616A (de) |
KR (1) | KR19980701780A (de) |
AT (1) | ATE202107T1 (de) |
AU (1) | AU694611B2 (de) |
CA (1) | CA2210966A1 (de) |
DE (1) | DE69613347T2 (de) |
DK (1) | DK0805812T3 (de) |
ES (1) | ES2159721T3 (de) |
GR (1) | GR3036560T3 (de) |
IL (1) | IL116406A0 (de) |
MX (1) | MX9705675A (de) |
PT (1) | PT805812E (de) |
WO (1) | WO1996022991A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133275A (en) * | 1998-05-06 | 2000-10-17 | Abbott Laboratories | 3-phenylpyrrolidine alpha-1 adrenergic compounds |
US6930101B1 (en) | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
US6730065B1 (en) * | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
US8889112B2 (en) * | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
US20020082288A1 (en) * | 1999-09-16 | 2002-06-27 | Gerald Horn | Ophthalmic formulations comprising an imidazoline |
US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
MXPA02010693A (es) * | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Compuestos ciclicos. |
US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
CA2433778A1 (en) | 2001-02-14 | 2002-08-22 | William Glen Harter | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
WO2002068419A1 (fr) | 2001-02-26 | 2002-09-06 | Tanabe Seiyaku Co., Ltd. | Derive de pyridopyrimidine ou naphthyridine |
JP2006503812A (ja) * | 2002-07-17 | 2006-02-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−2阻害薬との組み合わせ |
US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
US8170803B2 (en) | 2004-07-13 | 2012-05-01 | Dexcom, Inc. | Transcutaneous analyte sensor |
KR20070046176A (ko) | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도 |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US20100291151A1 (en) * | 2009-04-21 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
WO2014121028A1 (en) | 2013-02-01 | 2014-08-07 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
JP6335927B2 (ja) | 2013-02-01 | 2018-05-30 | オキュラリス・ファーマ・リミテッド・ライアビリティ・カンパニーOcularis Pharma, Llc | フェントラミンの水性点眼液およびそれらの医学的用途 |
EP3870170A4 (de) | 2018-10-26 | 2022-07-20 | Ocuphire Pharma, Inc. | Verfahren und zusammensetzungen zur behandlung von presbyopie, mydriasis und anderen augenerkrankungen |
US20220274915A1 (en) * | 2019-08-29 | 2022-09-01 | Sumitomo Chemical Company, Limited | Method for producing isocyanate compound |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU560459B2 (en) * | 1982-06-01 | 1987-04-09 | Abbott Laboratories | Tetrahydro-benzo(e) isoindolines |
US5089519A (en) * | 1988-01-15 | 1992-02-18 | Abbott Laboratories | Aminomethyl-chroman compounds |
EP0325963B1 (de) * | 1988-01-15 | 1993-09-22 | Abbott Laboratories | 1-Aminomethyl-1,2,3,4-tetrahydronaphthaline und -indane |
AU639615B2 (en) * | 1990-10-09 | 1993-07-29 | Otsuka Pharmaceutical Co., Ltd. | Pyrimidine derivative, production thereof, and androgen inhibitor |
US5158953A (en) * | 1991-08-13 | 1992-10-27 | National Science Council | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof |
US5288749A (en) * | 1991-12-20 | 1994-02-22 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
US5521181A (en) * | 1995-01-27 | 1996-05-28 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
-
1995
- 1995-06-05 US US08/465,476 patent/US5792767A/en not_active Expired - Fee Related
-
1996
- 1996-01-11 DE DE69613347T patent/DE69613347T2/de not_active Expired - Fee Related
- 1996-01-11 KR KR1019970705177A patent/KR19980701780A/ko active IP Right Grant
- 1996-01-11 AT AT96903364T patent/ATE202107T1/de not_active IP Right Cessation
- 1996-01-11 WO PCT/US1996/000178 patent/WO1996022991A1/en active IP Right Grant
- 1996-01-11 AU AU47473/96A patent/AU694611B2/en not_active Ceased
- 1996-01-11 PT PT96903364T patent/PT805812E/pt unknown
- 1996-01-11 MX MX9705675A patent/MX9705675A/es unknown
- 1996-01-11 CA CA002210966A patent/CA2210966A1/en not_active Abandoned
- 1996-01-11 ES ES96903364T patent/ES2159721T3/es not_active Expired - Lifetime
- 1996-01-11 JP JP8522872A patent/JPH11501616A/ja active Pending
- 1996-01-11 DK DK96903364T patent/DK0805812T3/da active
- 1996-01-11 EP EP96903364A patent/EP0805812B1/de not_active Expired - Lifetime
- 1996-12-15 IL IL11640695A patent/IL116406A0/xx unknown
-
2001
- 2001-09-06 GR GR20010401414T patent/GR3036560T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1996022991A1 (en) | 1996-08-01 |
GR3036560T3 (en) | 2001-12-31 |
EP0805812A1 (de) | 1997-11-12 |
KR19980701780A (ko) | 1998-06-25 |
IL116406A0 (en) | 1996-12-15 |
PT805812E (pt) | 2001-11-30 |
ES2159721T3 (es) | 2001-10-16 |
JPH11501616A (ja) | 1999-02-09 |
EP0805812B1 (de) | 2001-06-13 |
ATE202107T1 (de) | 2001-06-15 |
DE69613347D1 (de) | 2001-07-19 |
US5792767A (en) | 1998-08-11 |
DK0805812T3 (da) | 2001-09-17 |
AU694611B2 (en) | 1998-07-23 |
CA2210966A1 (en) | 1996-08-01 |
AU4747396A (en) | 1996-08-14 |
MX9705675A (es) | 1997-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69613347D1 (de) | Bizyklisch substituierte hexahydrobenz(e)isoindole mit alpha-1-adrenerg antagonistischer wirkung | |
ES2149451T3 (es) | Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido. | |
ATE204857T1 (de) | Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren | |
DE69422303D1 (de) | Neue 4-piperidinyl substituierte lactame als neukokinin 2 rezeptor antagonisten zur behandlung von asthma | |
AU6999796A (en) | Heterocyclic compounds as bradykinin antagonists | |
DE69707497D1 (de) | Benzopyranopyrrole und benzopyranopyridine mit alpha-1 adrenergische wirkung | |
DE69819166D1 (de) | 8-substituierte-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepin derivate als ampa/kainate-rezeptor-hemmer | |
MX9708557A (es) | Nuevo uso farmacologico de los antagonistas del receptor aii. | |
GR3032950T3 (en) | Substituted fused and bridged bicyclic compounds as therapeutic agents | |
DE69324492T2 (de) | 1-azaadamantanderivate als 5-ht4 agonisten oder antagonisten und/oder 5-ht3 antagonisten | |
ATE216233T1 (de) | Indolditerpen alkaloide | |
YU11494A (sh) | Postupak za dobijanje derivata piperazinilkamforsulfonila kao antagonista oksitocina | |
BR9713682A (pt) | Compostos alfa - 1 adrenergicos de benzopiranopirrol e benzopiranopiridina | |
HUP9900606A2 (hu) | 5-HT3 Receptor antagonisták mozgászavar kezelésére | |
DE69903930T2 (de) | N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen | |
JPS5791987A (en) | Aminoquinazoline derivative and its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |